In a significant move that could redefine the landscape of retinal disease treatment in Asia, Kiora Pharmaceuticals has inked a transformative partnership with Senju Pharmaceutical. The collaboration is centered on the development of KIO-301, a promising new therapeutic candidate for inherited degenerative diseases like Retinitis Pigmentosa (RP). This partnership aims to tap into Kiora’s developmental […]
Category: pharmaceutical innovation in asia
Partnership for Retinal Disease Treatment in Asia
In a groundbreaking collaboration, Kiora Pharmaceuticals and Senju Pharmaceutical have joined forces to propel the development of KIO-301, a potential therapeutic for retinal diseases. The partnership, which covers key Asian marketplaces including Japan and China, is a bold stride towards addressing the unmet medical needs of retinal patients in the region, underscoring both companies’ dedication […]